Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hunan Copote Science Technology Co Ltd
SSE:600476
|
CN |
|
Q
|
Qualcomm Inc
LSE:0QZ3
|
US |
Spexis AG
Total Current Assets
Spexis AG
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spexis AG
SIX:SPEX
|
Total Current Assets
CHf11.1m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Assets
$2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
29%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Assets
CHf251.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Assets
CHf223.8m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Assets
CHf82.7m
|
CAGR 3-Years
38%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Current Assets
CHf15.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Spexis AG
Glance View
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
See Also
What is Spexis AG's Total Current Assets?
Total Current Assets
11.1m
CHF
Based on the financial report for Dec 31, 2023, Spexis AG's Total Current Assets amounts to 11.1m CHF.
What is Spexis AG's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-39%
Over the last year, the Total Current Assets growth was 258%. The average annual Total Current Assets growth rates for Spexis AG have been -33% over the past three years , -39% over the past five years .
